Mounjaro: The Diabetes Drug Behind Weight-Loss Headlines
Mounjaro became famous for something it was never approved to do. Its actual licence, the one it was built, tested and submitted for, is type 2 diabetes, and the evidence behind that licence is deeper than most people realise: five major trials, a four-year cardiovascular outcomes study in more than thirteen thousand patients, and a paediatric approval that its weight-loss sibling does not have. This is the half of the Mounjaro story that the headlines skipped.
What Mounjaro is licensed for
Mounjaro is Eli Lilly's brand name for tirzepatide, approved by the FDA in May 2022 as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. In December 2025, that indication was extended to children aged 10 and older.
It is a once-weekly subcutaneous injection, given in the abdomen, thigh or upper arm, at any time of day, with or without meals. It is supplied as single-dose pens and as the multi-dose KwikPen.
What it is not licensed for, in the United States, is weight loss. That distinction sounds pedantic. It has significant consequences for coverage, documentation and access, and it is the source of nearly all the confusion around this drug.
Mounjaro, Zepbound, and one molecule
Mounjaro and Zepbound contain the same active ingredient at the same doses, made by the same company. Zepbound holds the weight-management and sleep-apnea indications; Mounjaro holds the diabetes indication. Two labels, two insurance categories, one molecule.
Outside the United States, the split often doesn't exist. In the United Kingdom, Zepbound is not licensed at all — Mounjaro carries the weight-management licence there. In India, Mounjaro launched for type 2 diabetes and is prescribed off-label by physicians for weight management, which is exactly how tirzepatide was used in the US for the two years before Zepbound existed as a separate brand.
So the answer to "is Mounjaro or Zepbound better" depends entirely on where you live and what you are being treated for. Pharmacologically, the question is empty.
How it lowers blood sugar without causing lows
Tirzepatide activates two gut hormone receptors — GIP and GLP-1 — from a single molecule. Both hormones are released after eating, and both tell the pancreas to secrete insulin.
The critical feature is that this insulin response is glucose-dependent. The signal amplifies insulin release when blood sugar is elevated and quiets down when it isn't. That is fundamentally different from insulin itself or from sulfonylureas, which push insulin out regardless of what glucose is doing — which is why those drugs cause hypoglycaemia and tirzepatide, on its own, largely does not.
Alongside insulin secretion, tirzepatide suppresses glucagon — the hormone that instructs the liver to release stored glucose. Across therapeutic doses, that suppression is substantial, and it removes a major source of the elevated fasting glucose that characterises type 2 diabetes. It also slows gastric emptying, blunting the post-meal glucose spike.
The dual-receptor design appears to matter here in a way that goes beyond appetite. Improvements in insulin sensitivity on tirzepatide are only partly explained by weight loss; a meaningful share appears to come from direct remodelling of fat tissue. In diabetes terms, that is the difference between a drug that helps because patients get smaller and a drug that helps because the underlying metabolic machinery works better.
What the SURPASS trials found
Mounjaro's diabetes evidence comes from the SURPASS programme — a series of phase 3 trials testing tirzepatide against placebo and, more usefully, against the drugs it would actually compete with.
SURPASS-2 is the one worth knowing. It put tirzepatide directly against semaglutide — the active ingredient in Ozempic — in 1,879 adults with type 2 diabetes already taking metformin, over 40 weeks. Tirzepatide reduced HbA1c by 2.01%, 2.24% and 2.30% at the 5, 10 and 15 mg doses, against 1.86% for semaglutide 1 mg. Weight fell by 7.6, 9.3 and 11.2 kg respectively, against 5.7 kg. All three doses met both non-inferiority and superiority thresholds on both endpoints.
There is an important caveat that gets left out of most summaries: semaglutide was tested at 1 mg, which was the standard maintenance dose at the time but is no longer the highest available. No completed head-to-head trial has compared the two molecules at their current maximum approved doses. Nausea rates, incidentally, were broadly comparable between the two groups.
SURPASS-4 tested tirzepatide against insulin glargine in 2,002 adults with type 2 diabetes and elevated cardiovascular risk, already on one to three oral agents, over 104 weeks. Tirzepatide also outperformed insulin degludec on HbA1c reduction over 52 weeks in a separate comparison.
Across the programme, effectiveness held up regardless of age, sex, race, ethnicity, region, baseline BMI, baseline HbA1c, diabetes duration or kidney function — a consistency that is genuinely unusual in diabetes trials.
| Trial | Compared against | Key finding |
|---|---|---|
| SURPASS-2 | Semaglutide 1 mg | HbA1c −2.30% vs −1.86%; weight −11.2 kg vs −5.7 kg at highest dose |
| SURPASS-4 | Insulin glargine | Superior glycaemic control in patients with elevated cardiovascular risk |
| SURPASS-CVOT | Dulaglutide 1.5 mg | Non-inferior on major cardiovascular events over a median 4 years |
| SURPASS-PEDS | Placebo | Supported approval in children aged 10 and older |
The cardiovascular question, finally answered
For years, tirzepatide had a gap in its file. Older GLP-1 drugs had proven they reduce cardiovascular events. Tirzepatide was assumed to do the same, but assumption is not evidence, and clinicians treating high-risk patients tended to prescribe what had been demonstrated rather than what seemed likely.
SURPASS-CVOT closed that gap. It enrolled 13,299 adults aged 50 and over with type 2 diabetes and established cardiovascular disease, and followed them for a median of four years.
The trial design deserves a note, because it was unusual. Giving placebo to people with established cardiovascular disease was considered unethical, so this became the first cardiovascular outcomes trial in the class to use an active comparator — dulaglutide, a GLP-1 drug already proven to reduce cardiovascular events. Beating a placebo is one thing. Matching a drug that already works is a much harder test.
Three-point major adverse cardiovascular events — cardiovascular death, heart attack or stroke — occurred in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group. That is roughly 8% fewer events, and it comfortably met the pre-specified non-inferiority threshold. It did not, however, reach formal statistical superiority on that primary endpoint, and it is worth being precise about that rather than rounding it up.
Where the results went further:
- A broader composite that also counted coronary revascularisation was significantly lower with tirzepatide — 16.5% versus 18.5%.
- All-cause mortality was around 16% lower.
- Kidney function, HbA1c, blood pressure and lipids all improved more with tirzepatide.
Those secondary findings were not adjusted for multiple comparisons, which means they should be read as strongly suggestive rather than definitive. The honest summary is that tirzepatide preserved the cardiovascular benefit established for earlier drugs in the class while delivering better metabolic and renal outcomes — and that discontinuation due to adverse events was somewhat higher (13.3% versus 10.2%).
A further trial, SURMOUNT-MMO, is examining whether the same cardiovascular benefit extends to people with obesity who have not developed diabetes.
The diabetes numbers
- 2.0–2.3% HbA1c reduction across the SURPASS dose range
- Superior to semaglutide 1 mg on both blood sugar and weight in the only head-to-head diabetes trial
- 13,299 patients, 4 years of cardiovascular outcomes data against an active comparator
- Approved from age 10 for type 2 diabetes — an indication Zepbound does not carry
The paediatric approval nobody talks about
In December 2025, the FDA extended Mounjaro's licence to children aged 10 and older with type 2 diabetes, based on the SURPASS-PEDS trial. Health Canada followed in July 2026 for ages 10 to 17.
The trial studied 5 mg and 10 mg doses in combination with metformin and/or basal insulin. The dose ladder is the same as for adults — 2.5 mg increments, minimum four weeks per step — but the maximum is lower. The safety profile matched what was seen in adults: mostly mild-to-moderate gastrointestinal effects, concentrated during escalation and easing over time.
One boundary is worth stating clearly, because it is widely misunderstood: this approval is for type 2 diabetes, not for paediatric obesity. Doctors do not prescribe Mounjaro to children who do not have diabetes, regardless of weight.
The reason this matters is that type 2 diabetes in adolescents behaves more aggressively than in adults, tends to respond poorly to metformin alone, and has historically had very few treatment options. A licensed second-line therapy is a meaningful addition, and it is one Zepbound does not have.
Side effects and safety
The dominant side effects are gastrointestinal — nausea, diarrhoea, vomiting, constipation and abdominal pain — and they cluster around dose increases. The escalation schedule exists precisely to manage this: 2.5 mg for the first four weeks, then 5 mg, then 2.5 mg increments at intervals of at least four weeks. The 2.5 mg starting dose is explicitly stated in the label as an initiation dose, not a treatment dose.
Mounjaro carries a boxed warning for thyroid C-cell tumours, based on rodent studies where tirzepatide produced dose- and duration-dependent increases in these tumours. Human relevance is undetermined. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, anyone with Multiple Endocrine Neoplasia syndrome type 2, and anyone with serious hypersensitivity to tirzepatide or its excipients.
Other labelled concerns include pancreatitis, acute gallbladder disease, serious hypersensitivity reactions including anaphylaxis and angioedema, worsening of diabetic retinopathy, and acute kidney injury — the last usually secondary to dehydration from vomiting or diarrhoea, which is why fluid intake genuinely matters during dose escalation.
The hypoglycaemia nuance
On its own, Mounjaro rarely causes low blood sugar, because its insulin effect is glucose-dependent. Combined with a sulfonylurea or with insulin, the picture changes completely — the risk of hypoglycaemia, including severe hypoglycaemia, rises meaningfully. The label's guidance is to consider reducing the dose of the sulfonylurea or insulin when starting Mounjaro.
This is one of the most clinically important details about the drug and one of the least discussed in general coverage. It is also a concrete illustration of why prescriber supervision is not a formality in diabetes: someone has to adjust the other medications.
Three interactions that get missed
Oral contraceptives. Because Mounjaro delays gastric emptying, it can reduce the absorption of oral contraceptives. The label advises switching to a non-oral method, or adding a barrier method, for four weeks after starting — and for four weeks after every dose increase. Given the ladder runs to 15 mg, that is a recurring window, not a one-time precaution.
Other oral medications. The same delayed-emptying effect can alter absorption of anything taken by mouth. Drugs with a narrow therapeutic index — warfarin is the label's example — warrant monitoring.
Insulin. If both are used, they are given as separate injections into different sites, and are never mixed in the same syringe.
Where research compounds fit — and where they don't
Tirzepatide is also studied as a molecule outside the branded pharmaceutical context, and that is a legitimate area of research interest. It is worth being exact about the difference.
A research-grade compound is characterised material supplied for laboratory work. What it does not include is the thing that makes Mounjaro a diabetes treatment: a prescriber who adjusts your sulfonylurea dose, a pharmacist who flags the contraceptive interaction, monitoring for retinopathy progression, a titration schedule someone is accountable for, and a manufacturing and adverse-event reporting system behind the vial. In a condition like type 2 diabetes — where the drug interacts with other glucose-lowering agents and where getting it wrong produces hypoglycaemia rather than just discomfort — that infrastructure is a substantial part of the safety profile.
For laboratory research, independent verification of identity and purity is the baseline rather than a bonus. Our COA database holds third-party testing across the catalogue, including tirzepatide, semaglutide and the triple agonist retatrutide.
If you have type 2 diabetes and are considering treatment, that decision belongs with a clinician who can see your full medication list.
Explore the metabolic research category
Browse our research-grade metabolic and incretin compounds, each supplied with third-party laboratory testing and handled under controlled cold-chain conditions.
View metabolic peptidesFrequently asked questions
Is Mounjaro approved for weight loss?
Not in the United States. Mounjaro is licensed for type 2 diabetes; Zepbound holds the weight-management indication, and both contain tirzepatide. In some other countries, including the United Kingdom, Mounjaro carries the weight-management licence and Zepbound is not marketed at all.
How much does Mounjaro lower HbA1c?
Across the SURPASS trials, HbA1c reductions ranged from roughly 2.0% to 2.3% depending on dose. In the head-to-head SURPASS-2 trial, the 15 mg dose reduced HbA1c by 2.30% compared with 1.86% for semaglutide 1 mg over 40 weeks.
Does Mounjaro cause low blood sugar?
Rarely on its own, because its effect on insulin is glucose-dependent — it amplifies insulin release when blood sugar is high and quiets when it is not. The risk rises substantially when it is combined with insulin or a sulfonylurea, which is why the label advises considering a dose reduction of those medications when starting.
Does Mounjaro protect the heart?
SURPASS-CVOT followed 13,299 people with type 2 diabetes and established cardiovascular disease for a median of four years, comparing tirzepatide against dulaglutide. Tirzepatide met non-inferiority on major cardiovascular events, with roughly 8% fewer events, and showed significantly lower rates on a broader composite that included coronary revascularisation. It did not reach formal superiority on the primary endpoint.
Can children take Mounjaro?
Yes, for type 2 diabetes, from age 10 — approved in the US in December 2025 and in Canada in 2026. The dose ladder mirrors the adult schedule but with a lower maximum. It is not prescribed to children for obesity in the absence of type 2 diabetes.
Does Mounjaro affect birth control?
It can. By slowing gastric emptying, it may reduce absorption of oral contraceptives. The label advises using a non-oral method or adding a barrier method for four weeks after starting and for four weeks after each dose increase.
The bottom line
Mounjaro is a diabetes drug that happens to produce substantial weight loss, not a weight-loss drug that happens to help diabetes. The distinction shapes everything about how it is studied, prescribed, covered and monitored.
On its own terms, the file is strong: the largest HbA1c reductions of any injectable in the class, superiority over both semaglutide 1 mg and basal insulin in direct comparisons, four years of cardiovascular outcomes data against an active comparator rather than a placebo, and a paediatric licence for a population with almost no other options.
What it is not is simple. The interaction profile is real, the hypoglycaemia risk changes entirely depending on what else is in the regimen, and the drug works only while it is being taken. Those are the reasons this sits with a prescriber rather than in a shopping cart.
For more on how these compounds compare, our Info Center covers each individually, and the metabolic category groups them by research application.
Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Ozempic®, Wegovy® and Trulicity® are registered trademarks of their respective owners. Peptides Costa Rica is not affiliated with, endorsed by, or sponsored by these companies, and does not sell these branded products. This article is provided for educational and informational purposes only. It is not medical advice, and it is not intended to diagnose, treat, cure or prevent any condition. Tirzepatide is a prescription medicine and should only be used under the supervision of a licensed healthcare professional. Products offered by Peptides Costa Rica are intended strictly for laboratory research use only. They are not approved or licensed by the FDA for the prevention, diagnosis, treatment or cure of any disease. Not for human or veterinary use.
